Prostate – Specific Antigen (Psa) as a Screening Tool for Benign Prostate Hyperplasia (Bph) and Prostate Cancer (Pca) in Sulaimani Province
Keywords:
Prostatic specific antigen, Free PSA, Prostate cancer, BPH, Prostatits, cPSA, tPSAAbstract
The current study was applied to evaluate the significance of serum Prostate- Specific Antigen (PSA) as a screening tool for the PCa and the role of percent free - to- total PSA ratio in the discriminating between BPH and PCa. Prostatic biopsies and blood were collected from (62) patients aged between (50-89) years. Eleven healthy men with negative digital rectal examination, (median age, 60.6yr) were enrolled in this study as a control group. The common diseases encountered were BPH (59.7%), BPH with prostatitis (19%), adenocarcinoma (17.7%), and transitional cell carcinoma (3.2%). 54% of BPH cases had tPSA level < 4 ng/ml as well 13.5% of them having tPSA>10, while 15.3% of malignant cases had tPSA level < 4 ng/ml and 84.7% of them having tPSA>10. The statistical analysis showed a significant difference between (BPH and PCa); (PCa and control cases) and (prostatitis and control) in regard to tPSA. Regarding to % cPSA the entire case of PCa showed levels >60% aligned with only 75%, 27%, 16% in prostatitis, control and BPH groups successively. The mean comparison showed statistically significant differences between the PCa patients and control cases and between prostatitis and control cases, while no significant differences between BPH and control group. Regarding to % FPSA, 53.8 % of PCa cases showed ≤15, along with 16.6 % of prostatitis showed ≤15, while no cases of both BPH and control revealed FPSA ≤15. Comparison of the means showed a statistically large difference between the (PCa and BPH), (PCa and control) and (prostatitis and control) cases. While no significant differences between (BPH and control) cases. In conclusion, combinational use of tPSA with other molecular forms of PSA especially proportion of FPSA provide higher diagnostic and differentiative accuracy than the tPSA alone.
References
Brett, T. (2011). Prostate specific Antigen. Australian Family Physician. 40 (7):497-500.
bioMerieux. (2007). Prostate Specific Antigen (VIDAS PSA assay kit; the information booklet), bioMerieux Incorporation, France: 2-3.
Catalona, W.J., Beiser, J.A., and Smith, D.S. (1997). Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol. 158:2162-2167.
Catalona,W.J., Smith, D.S., Ratliff, T.L., Dodds, K.M., Coplen, D.E., and Yuan, J.J.
(1991). Measurement of prostate-specific antigen in serum as a screeningtest for prostate cancer. N Engl J Med. 325:1324.
Catalona, W.J., Smith, D.S., Ratliff, T.L., and Basler, J.W. (1993). Detection of organ confined prostate cancer is increased through prostate-specific antigen based screening. JAMA. 270: 948-954.
Christensson, A., Bjork, T., and Nilsson, O. (1993). Serum prostate specific antigen complexed to a1-antichymotrypsin as an indicator of prostate cancer. J Urol. 150:100- 105.
Etzioni, R., Seth, F., Peter, H.G., Charles, L.K., David, F.P., and Meir, J.S. (2004).
Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?. Cancer Epidemiol Biomarkers Prev. 13(10): 1640-1645.
Gerstenbluth, R.E., Seftel, A.D., Hampel, N.O., Oefelein, M.G., and Resnick, M. (2000). The accuracy of the increased prostate specific antigen levels (greater than an equal to 20 ng/ml) in predicting prostate cancer; is biopsy always required? J Urol. 168:
Hsing, A.W., and Chokkalingam, P.A. (2006). Prostate cancer epidemiology. Frontiers in Bioscience. 11:1388-1413.
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, J. and Thun, M. J.(2005). Cancer statistics 2005CA Cancer. J. Clin. 55: 10-30.
Jung, K., Ulrike, E., Michael, L., Brigitte, B., Pranav, S., Birgit, R., Steffen, H., Dietmar, S., and Stefan, A.L. (2000). Ratio of free or complexed prostate specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clinical Chemistry 46:1:55–62.
Kumar, P. (2004) Role of Prostate Specific Antigen in Differentiating Various Prostatic Pathology, Ph.D. thesis, Tribhuvan University, Nepal ,:15-49.
Lilja, H., Christensson, A., and Dahlen, U. (1991). Prostate-specific antigen in serum occurs prdominantly in complex with alpha-1- antichymlotrypsin. Clin Chem. 7:1618-1625.
Lilja, H., Piironen, T.P., and Rittenhouse, H.G. (2000). Prostate-specific antigen. In Vogelzang NJ, Shipley WU, Scardino PT, Coffey DS eds, Comprehensive Textbook of Genitourinary Oncology . Philadelphia: Lippincott, Williams and Wilkins Publishers: 638–650
Magklara, A., Andreas, S., William, J.C., and Eleftherios, P.D. (1999).The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clinical Chemistry. 45(11): 1960–1966.
Mitchell, D.M., Swindell, R., Elliott, T., Wylie, J.P., Taylor, C.M.,and logue, J.P.. (2008).
Analysis of prostate-specific bounce after i(125) permanent seed implant for localized prostate cancer. Radiother Oncol. 88:102–107.
Modi, P., Helfand, B.T., and McVary, K.T. (2010). Modifications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen. Curr Urol Rep.11:224-227.
Oesterling, .J.E. (1995). Prostate specific antigen: its role in the diagnosis and staging of prostate cancer. Cancer. 75:1795-1804.
Oesterling, J.E., Jacobsen, S.J., and Chute, C.G. (1993). Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA; 270:860-864.
Potts, J., and Payne, R.E. (2007). Prostatitis: Infection, neuromuscular disorder, or pain syndrome? Proper patient classification is key. Cleveland Clinic Journal of Medicine; 74:64-66.
Stacy, Loeb, A.H., Ballentine Carter, B., William, J., Catalona, C., Judd, W., Moul, D., Fritz, H., and Schroder, E. (2012). Baseline Prostate-Specific Antigen Testing at a Young Age. European Urology. 61: 1–7.
Zhang, W.M., Leinonen, J., Kalkkinen, N., and Stenman, U.H. (1997). Prostate specific antigen forms a complex with and cleaves alpha 1-protease inhibitor in vitro. Prostate. 33: 87–96.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License [CC BY-NC-SA 4.0] that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work, with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online.
